DSGN says DT-216 delivered biomarker and clinical gains in Friedreich ataxia
DSGN’s DT-216 showed strong proof of concept in Friedreich ataxia, with significant biomarker and functional improvements. The company expects a 12-week efficacy readout in Q1 2027 and says its DM1 program is advancing with a novel DNA-targeting approach.